EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cathepsin B‐Responsive Dendronized‐Hyaluronic Acid Nanomedicine for Simultaneous Cancer Theranostics

Chunhua Guo, Yujun Zeng, Yuan Ou, Zhongwei Gu, Kui Luo

MedComm – Oncology · 2025-09 · 4 (3)

DOI: 10.1002/mog2.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 04.08.2025. Verfasst von Chunhua Guo und 4 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor microenvironment‐responsive imaging‐guided therapy has emerged as a novel approach for malignant tumor prognosis and therapy. A multifunctional nanoscale drug delivery system is often employed to realize diagnosis, treatment, monitoring, and evaluation by combining a therapeutic unit and an imaging unit to enable. In this study, we designed and prepared a theranostic nanomedicine by conjugating a small‐molecular gadolinium chelate (Diethylenetriaminepentaacetic acid Gadolinium[III] chelate, Gd‐DOTA) and a chemotherapeutic drug paclitaxel (PTX) via a cathepsin B‐responsive linker (glycylphenylalanylleucylglycine, Gly‐Phe‐Leu‐Gly, GFLG) onto a peptide dendron‐hyaluronic acid (HA) hybrid. Upon reaching the tumor microenvironment, the GFLG linker was cleaved by overexpressed cathepsin B, leading to simultaneous release of PTX for targeted chemotherapy and Gd‐DOTA for enhanced magnetic resonance imaging (MRI). The experiments demonstrated that the theranostic nanomedicine significantly enhanced MRI contrast and exhibited superior antitumor efficacy in 4T1 breast tumor models without pronounced systemic toxicity. Importantly, under the tumor microenvironment, effective release and clearance of Gd‐DOTA from the hybrid postimaging reduced the risk of long‐term toxicity. This study presents a feasible approach for cancer theranostics by integrating precise imaging, targeted therapy, and rapid clearance of toxic drugs in a single platform. This promising nanomedicine could be explored for clinical translation.

Zitieren

APA

Guo, C., Zeng, Y., Ou, Y., Gu, Z., & Luo, K. (2025). Cathepsin B‐Responsive Dendronized‐Hyaluronic Acid Nanomedicine for Simultaneous Cancer Theranostics. MedComm – Oncology, 4(3). https://doi.org/10.1002/mog2.70035

Vancouver

Guo C, Zeng Y, Ou Y, Gu Z, Luo K. Cathepsin B‐Responsive Dendronized‐Hyaluronic Acid Nanomedicine for Simultaneous Cancer Theranostics. MedComm – Oncology. 2025;4(3). doi:10.1002/mog2.70035

BibTeX
@article{Guo2025,
  author = {Guo, Chunhua and Zeng, Yujun and Ou, Yuan and Gu, Zhongwei and Luo, Kui},
  title = {Cathepsin B‐Responsive Dendronized‐Hyaluronic Acid Nanomedicine for Simultaneous Cancer Theranostics},
  journal = {MedComm – Oncology},
  year = {2025},
  volume = {4},
  number = {3},
  doi = {10.1002/mog2.70035}
}
Kostenlos starten →